🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and Serologic

RecruitingNAAges 18 Years - 59 YearsAllUniversity Hospital, Montpellier
NCT05962177 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Several prospective monocentric cohorts of between 250 and 1000 patients have been set up in order to characterize more precisely the evolution of the disease. Nevertheless, due to an initial recruitment carried out in the years 2000-2010, they do not constitute a faithful representation of the patients followed in clinical routine, in particular in terms of distribution of treatments. Indeed, the introduction, about 10 years ago, of high efficacy treatments (HET) has changed the management of the disease and a significant proportion of patients not controlled by medium efficacy treatments (MET) of the disease are now stable on HET. Nevertheless, if their short-term efficacy has been clearly demonstrated, it remains important to be able to confirm the superiority of HET over MET with the help of prospective cohorts (thus ensuring a retention of patients \> 90% over the long term) analyzi

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients over 18 and under 60 years of age * Patients with Relapsing-remitting MS without relapse for at least 6 months * EDSS\<6 at time of inclusion Exclusion Criteria: * Secondary progressive MS or Primary progressive MS at time of inclusion * Evidence of disease progression (clinical or radiological) * Change in treatment within 6 months prior to inclusion * Subject with a contraindication to MRI (claustrophobia, pacemaker, etc.) * Inability to follow the follow-up planned by the study * Pregnant or breastfeeding women * Patient not affiliated to the social security system or not benefiting from such a system * Adult protected by law or patient under guardianship or curatorship * Failure to obtain written informed consent after a reflection period
💊

What it tests

  • Magnetic Resonance Imaging
  • Blood withdrawal
  • Neuropsychological tests
📍

Where

1 site
Neurology Department, Hopital Gui de Chauliac
Montpellier, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy